Kyverna Therapeutics, Inc. KYTX Non Cash Lease Expense
Non Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept kytx:NonCashLeaseExpense.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s non cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s non cash lease expense?
- Kyverna Therapeutics, Inc. (KYTX) reported non cash lease expense of $619K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s non cash lease expense changed year-over-year?
- Kyverna Therapeutics, Inc.'s non cash lease expense decreased by 12.1% year-over-year, from $704K to $619K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s non cash lease expense?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s non cash lease expense has grown at a 29.8% compound annual growth rate (CAGR), from $1.72M to $2.9M.
- What does non cash lease expense mean?
- This metric captures the portion of lease expenses that does not involve an immediate cash outflow, typically related to the amortization of right-of-use assets. It is used to adjust net income to arrive at cash flow from operations by removing non-cash accounting charges. Monitoring this helps investors understand the underlying cash impact of the company's real estate and equipment leasing obligations.